Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 8.01 (Other Events). Total debt issuance $8.0B across 7 tranches, maturities ranging 2028–2066, completed March 4, 2026.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Total debt issuance $8.0B across 7 tranches, maturities ranging 2028–2066, completed March 4, 2026
- Floating rate tranche $750M due 2028; fixed rates range from 3.775% (2028) to 5.650% (2066)
- Largest tranches: $1.5B at 3.775% (2028) and $1.5B at 4.750% (2036)
- All notes unsecured, senior ranking: pari passu with existing AbbVie debt obligations
- Scale of offering signals significant capital need, likely for debt refinancing, acquisitions, or general corporate purposes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.